TNXT:NASDAQT. Rowe Price Innovation Leaders ETF Analysis
Data as of 2026-06-17 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
TNXT is a brand‑new ETF (inception 28 Jan 2026) that targets innovation‑driven companies in technology, healthcare and finance. The fund’s price sits just below its 30‑day resistance of $27.83 and above its 20‑day SMA ($26.96), indicating a short‑term bullish bias, while the RSI at 54.8 suggests momentum is still neutral. However, the MACD histogram is negative and the volume trend is decreasing, highlighting weakening short‑term thrust and a pronounced liquidity concern (average 10‑day volume ~1.5 k shares versus today’s 13 shares). With a beta of 1.43 and 30‑day volatility of 22 %, the ETF is more volatile than the market, and its max drawdown of roughly 13 % underscores the downside risk. The market sentiment is extremely greedy (Fear‑Greed Index 92), but the fund’s tiny asset base (~$18.7 M) and zero tracking error (active management) mean tracking risk is low while liquidity risk is high.
Market Outlook
Short Term
< 1 yearKey Factors
- price near resistance with bearish MACD histogram
- decreasing and very low trading volume
- moderate RSI indicating no overbought condition
Medium Term
1–3 yearsKey Factors
- exposure to secular innovation themes
- high beta offering upside in a bullish market
- reasonable expense ratio (0.49%) for an active fund
Long Term
> 3 yearsKey Factors
- long‑term growth potential of technology, healthcare and finance innovators
- historically strong performance of large‑growth innovation portfolios
- low tracking error and active management aligning with the fund’s mandate
Key Metrics & Analysis
Fund Metrics
Technical Analysis
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.